Protection against methacholine-induced bronchospasm: Salbutamol pMDI versus Clickhaler® DPI

European Respiratory Journal

Volumn 21, Issue 5, 2003, Pages 816-820

  Newhouse, M T ^a   Patel, P ^b   Parry Billings, M ^c  

^a ST JOSEPH S HOSPITAL   (Canada)

^b Allied Research International   (Canada)

^c Innovata Biomed Ltd   (United Kingdom)

Author keywords

Airway hyperresponsiveness; Bioequivalence; Clickhaler ; Dry powder inhaler; Methacholine challenge; Salbutamol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; METHACHOLINE; NEDOCROMIL; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

ARTICLE; ASTHMA; BIOASSAY; BRONCHODILATING ACTIVITY; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; METERED DOSE INHALER; NEBULIZER; POWDER INHALER; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALBUTEROL; BRONCHIAL PROVOCATION TESTS; BRONCHIAL SPASM; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; METHACHOLINE CHLORIDE; MIDDLE AGED; POWDERS;

EID: 0038394631     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00045902     Document Type: Article

References (33)

1. Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration. Interim guidance for documentation of in vivo bioeqUivalence of albuterol inhalation aerosols (metered dose inhalers). Rockville MD, FDA, 1994.
2. Snell NJC. Equivalence testing - the special case of inhaled medications. Int J Pharm Med 1998; 12: 245-246.
3. Leach CL. Approaches and challenges to use of freon propellant replacements. Aerosol Sci Technol 1995; 22: 328-334.
4. Dhand R, Fink J. Dry powder inhalers. Respir Care 1999; 44: 940-951.
5. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J 1997; 10: 2127-2138.
6. Timsina MP, Martin GP, Marriott C, Ganderton D. Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994; 101: 1-13.
7. Lofdahl C-G, Andersson L, Bondesson E, et al. Differences in bronchodilating potency of salbutamol in Turbuhaler® as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. Eur Respir J 1997; 10: 2474-2478.
8. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247-249.
9. Hindle M, Peers EM, Parry-Billings M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Br J Clin Pharmacol 1997; 43: 336-338.
10. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105-110.
11. Chrystyn H, Allen MB, Corlett SA, Tomlinson HS. Simultaneous measurement of pharmacodynamic and pharmacokinetic parameters which can be used to evaluate the equivalence of inhaled salbutamol. Am J Respir Crit Care Med 1998; 157: A636.
12. Hindle M, Newton PAG, Chrystyn H. Investigations of an optimal inhaler technique using urinary salbutamol as a measure of relative bioavailability to the lung. Thorax 1993; 48: 506-511.
13. Buck H, Parry-Billings M. Discriminating measures of bronchodilator drug efficacy and potency. Br J Clin Pharmacol 2001; 52: 245-253.
14. Ahrens RC. On comparing inhaled beta adrenergic agonists. Ann Allergy 1991; 67: 296-298.
15. Finney DJ. Statistical Methods in Biological Assay. 3rd Edn. London, Charles Griffin & Co. Ltd, 1978; pp. 105-147.
16. Juniper EF, Frith PA, Hargreave FE. Airway responsiveness to histamine and methacholine: relationship of minimum treatment to control symptoms of asthma. Thorax 1981; 36: 575-579.
17. Newhouse MT, Nantel NP, Chambers C, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 1999; 115: 952-956.
18. Siersted HC, Walker CM, O'Shaughnessy AD, Willan AR, Wiecek EM, Sears MR. Comparison of two standardized methods of methacholine inhalation challenge in young adults. Eur Respir J 2000; 15: 181-184.
19. Parameswaran K. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane β-agonists. J Allergy Clin Immunol 1999; 104: S243-S245.
20. Stewart BA, Ahrens RC, Carrier S, et al. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest 2000; 117: 714-721.
21. Blake KV, Hoppe M, Harman E, Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution: bioassay by histamine provocation. Chest 1992; 101: 309-315.
22. Ahrens RC, Harris JB, Milavetz G, Annis L, Ries RA. Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in asthmatic patients. J Allergy Clin Immunol 1987; 79: 876-882.
23. Parry-Billings M, Boyes RN, Clisby LM, Braithwaite P, Williams S, Harper AE. Design, development, and performance of a novel multidose dry-powder inhaler. Pharm Technol 1999: 23: 70-81.
24. Wong AG, O'Byrne PM, Lindbladh C, Inman MD, Stahl E, Hargreave FE. Dose-response protective effect of salbutamol on methacholine airway responsiveness using pressurized metered dose inhalers and Turbuhalers. Can Respir J 1998; 5: 119-123.
25. 2-agonist. Am J Respir Crit Care Med 1999; 160: 354-357.
26. Lalonde RL, Ouellet D, Kimanani EK, Potvin D, Vaughan LM, Hill MR. Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. J Pharmacokinet Biopharm 1999; 27: 67-83.
27. Derom E, Borgström L, Van Schoor J, Löfroos A-B, Pauwels R. Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals. Am J Respir Crit Care Med 2001; 164: 1398-1402.
28. Morice AH, Peake MD, Allen MB, Campbell JC, Parry-Billings M. Reproducibility of bronchodilator response for a reservoir dry powder inhaler following routine clinical use. J Asthma 2000; 37: 81-87.
29. Chege JK, Chrystyn H. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Respir Med 2000; 94: 51-56.
30. The International Pharmaceutical Aerosol Consortium (IPAC). Enviros March. Study on the use of HFCs for metered dose inhalers in the European Union. Final Report following Submission to the ECCP. http://www.ipacmdi.com/documents/Enviros_report.pdf. 1st December 2000 (accessed 27 February 2003).
31. McFadden ER Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol 1995; 96: 278-283.
32. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003; 16: 81-98.
33. Parry-Billings M, Birrell C, Oldham L, O'Callaghan C. Inspiratory flow rate through a dry powder inhaler (Clickhaler®) in children with asthma. Pediatr Pulmonol 2003; 35: 220-226.